CorMedix Inc. (NASDAQ:CRMD – Get Free Report) was the target of unusually large options trading on Wednesday. Traders purchased 4,771 call options on the company. This is an increase of approximately 790% compared to the typical daily volume of 536 call options.
CorMedix Stock Performance
Shares of NASDAQ CRMD opened at $3.33 on Thursday. The company has a market cap of $182.50 million, a PE ratio of -3.87 and a beta of 1.98. The business has a 50-day simple moving average of $3.48 and a two-hundred day simple moving average of $4.16. CorMedix has a fifty-two week low of $2.57 and a fifty-two week high of $6.09.
Insider Transactions at CorMedix
In other news, CEO Joseph Todisco purchased 10,000 shares of the company’s stock in a transaction dated Friday, September 8th. The shares were acquired at an average price of $3.71 per share, with a total value of $37,100.00. Following the transaction, the chief executive officer now owns 219,726 shares of the company’s stock, valued at $815,183.46. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Corporate insiders own 4.60% of the company’s stock.
Institutional Inflows and Outflows
Analyst Upgrades and Downgrades
A number of equities research analysts recently weighed in on CRMD shares. Needham & Company LLC dropped their price objective on CorMedix from $12.00 to $10.00 and set a “buy” rating on the stock in a research report on Wednesday. JMP Securities reissued a “market outperform” rating and issued a $19.00 price target on shares of CorMedix in a report on Wednesday. Royal Bank of Canada raised their price target on CorMedix from $6.00 to $10.00 and gave the stock an “outperform” rating in a report on Wednesday. Finally, Truist Financial reissued a “buy” rating and issued a $18.00 price target on shares of CorMedix in a report on Wednesday. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $14.25.
CorMedix Company Profile
CorMedix Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath and Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology.
- Five stocks we like better than CorMedix
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- New Disney investor propels stock to ranks of best S&P gainers
- How to Invest in Esports
- Buffett’s latest portfolio additions, trims, and cuts in Q3
- P/E Ratio Calculation: How to Assess Stocks
- 5 reasons TJX Companies will hit new highs in 2024
Receive News & Ratings for CorMedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorMedix and related companies with MarketBeat.com's FREE daily email newsletter.